Article citationsMore>>

H. Kantarjian, J. E. Cortes, D. W. Kim, P. DorlhiacLlacer, R. Pasquini, J. DiPersio, et al., “Phase III Study of Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients with Chronic Myeloid Leukemia in Accelerated Phase Resistant or Intolerant to Imatinib: 15-Month Median Follow-Up,” Blood, Vol. 113, No. 25, 2009, pp. 6322-6329. doi:10.1182/blood-2008-11-186817

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top